NFL Biosciences SA (ALNFL.PA)

EUR 1.88

(-2.59%)

Market Cap (In EUR)

18.24 Million

Revenue (In EUR)

-

Net Income (In EUR)

-3.74 Million

Avg. Volume

58.05 Thousand

Currency
EUR
Country
Healthcare
Open
-
Prev. Close
-
Day Range
-
Year Range
1.33-3.28
PE
-
EPS
-
Beta Value
1.7743019
ISIN
FR0014003XT0
CUSIP
-
CIK
-
Shares
-
Earnings Annoncement
-

Company Profile

Sector
Healthcare
Industry
Biotechnology
CEO
Dr. Ignacio Faus M.B.A., Ph.D.
Employee Count
-
Website
https://www.nflbiosciences.com
Ipo Date
2021-07-05
Details
NFL Biosciences SA, a biotechnology company, develops natural addiction withdrawal solutions for smokers. Its natural drug candidate in pipeline to cure tobacco addiction include NFL-101, a tobacco extract that is in Phase III clinical trial targeting smoking addiction; NFL-201, a cannabis and tobacco extract, which is in preclinical stage; and NFL-301, a botanical extract (traditional Chinese medicine) that is in preclinical stage. The company was incorporated in 2006 and is based in Castelnau-le-Lez, France.